Prevention uncovers clued-up patients

Share this article:
Consumers are getting savvier about the risks and benefits of the medicines they're taking, according to Prevention's 10th Annual National Survey on Consumer Reaction to DTC Advertising of Prescription Medications.

Moreover, those doing the most information-seeking are also often those most likely to ask their doctor about an advertised medicine. Overall, 27% of respondents saw a DTC ad and talked to their doctor about it, but 42% of those who said they know a lot about their illness reported doing so. 

The survey found that more consumers—61%, versus 46% in 2005—want to know how the effectiveness of the drugs they take compares to others in their class.

“What we're seeing is the evolution of consumers towards having questions beyond risk and benefits,” said Cary Silvers, director of consumer and advertising trends for Rodale. “Beyond that, people want to know how one medication compares to another, and that's being driven by the power of online search and the ability to comparison-shop for different products.”

They're also more curious about how the medicine treats their condition (76%, versus 70% in 2006) and how it interacts with other medicines (66%, versus 57% in 2006).

The survey also found that even after a prescription is filled, three-quarters of consumers are still looking for information about their medications, with 29% reporting that they stopped to watch or read an ad.

A vast majority of survey respondents—73%—said DTC ads allow them to be more involved with their healthcare, though only 8% reported asking their doctor for a specific medication after seeing an ad.

Disease awareness ads, however, seem to be having the desired effect. Among the 36% of consumers who remembered seeing any disease awareness ad, half said they had either talked with their doctor, a friend or family member or searched for additional information online.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.